Formulation and evaluation of preungual delivery system containing eugenol for the treatment of onychomycosis
Abstract
The purpose of the study was to formulate a Preungual delivery system containing Eugenol for the treatment of Onychomycosis. And to find out the best polymer concentration, concentration of penetration enhancers and to carry out the anti-fungal testing on the best formulation obtained. The in vitro diffusion studies were carried out in Franz diffusion cell using phosphate buffer pH 7.4 and methanol as medium, whereas the permeation studies were carried out using hooves membrane. The percentage of cumulative drug released was determined by a UV spectrophotometer. The formulation containing 10% w/v of ethyl cellulose along with 2.5%w/v thioglycolic acid and 2.5 %v/v of dimethyl sulfoxide showed a good release. Eugenol nail lacquer's sensitivity against Candida albicans was determined by measuring the zone of inhibition by comparing it with a standard drug. The formulation showed a zero-order release pattern and the Higuchi model for the mechanism of release.
Downloads
References
2. Anna Paula Krawczyk-Santos, Priscila B.R. da Rocha, Leandro L. Kloppel, Bruno dos S. Souza, Jorge Luiz V. Anjos, Antonio Alonso, Dalva Lúcia A. de Faria, Otávio M. Gil, Tais Gratieri, Ricardo N. Marreto, Stephania Fleury Taveria, Enhanced nail delivery of voriconazole-loaded nanomicelles by thioglycolic acid pre-treatment: A study of protein dynamics and disulfide bond rupture. Int j Pharma.2021;602:1-12
3. Nguyen, H.X.; Banga, A.K. Effect of ablative laser on in vitro transungual delivery. Int. J. Pharm. 2018, 544, 402–414
4. Donnelly, R.F., Mccarron, P.A., Lightowler, J.M., Woolfson, A.D. Bio adhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J. Control. Release. 2005;103: 381- 392.
5. Mertin D., Lippold BC. In vitro permeability of the human nail and of keratin membrane from bovine hooves: Influence of the partition coefficient octanol/water solubility of drug on their permeability and maximum flux. J Pharm Pharmacol 1997; 49:30-34.
6. Trepanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother. 1998; 32: 204-13.
7. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis. 1996; 23:305-13.
8. Gupta AK, Scher RK, Rich P Fluconazole for the treatment of onychomycosis: an update. Int J Dermatol. 1998; 37:815-20
9. Roberts DT. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails Dermatology. 1997; 194(suppl 1):37-9
10. Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992; 304:1151-
11. Jadhav BK, Khandelwal KR, Ketkar AR, Pisal SS. Formulation, and evaluation of mucoadhesive Nano capsules containing eugenol for the treatment of periodontal diseases. Drug Dev. Ind. Pharm. 30; 2004: 195-203.
12. K. Pramod, Shahid H. Ansari Javed Ali Development, and validation of UV spectrophotometric method for the quantitative estimation of eugenol. Asian J. Pharm. Ana. 2013; 3(2):58-61
13. Suvakanta Dash, Padala Narasimha Murthy, Lilakanta Nath and Prasanta Chowdhury. Kinetic modelling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica - Drug Research. 2010; 67: 217-223
14. Gautam Singhvi, Mahaveer Singh. In vitro drug release characterization models. International Journal of Pharmaceutical Studies and Research. 2011, 2:77-84.
15. A Srivastava, U Sohramau, Formulation and Evaluation of Nail Lacquer Containing Anti-fungal Griseofulvin for the Treatment of Onychomycosis,2021, International Journal of Innovative Science and Research Technology,294-306
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.